Evidence map›Paper›PMID 36209067›Full record

ArticleBMC psychiatry2022

Design of an RCT on cost-effectiveness of group schema therapy versus individual schema therapy for patients with Cluster-C personality disorder: the QUEST-CLC study protocol.

Iuno Z Groot, Anne-Sophie S M Venhuizen, Nathan Bachrach, Simone Walhout, Bregje de Moor, Kasper Nikkels, Susanne Dalmeijer, Myrte Maarschalkerweerd, Joël R van Aalderen, Hinde de Lange and 5 more

Erratum issuedOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Iuno Z Groot *Department of Clinical Psychology, University of Amsterdam, PO Box 15933, Amsterdam, 1001 NK, the Netherlands. i.z.groot@uva.nl.ORCID http://orcid.org/0000-0001-5744-4567
Anne-Sophie S M Venhuizen *Department of Clinical Psychology, University of Amsterdam, PO Box 15933, Amsterdam, 1001 NK, the Netherlands.
Nathan BachrachDepartment of medical and clinical psychology, Tilburg University, Tilburg, the Netherlands.ORCID http://orcid.org/0000-0002-0746-2692
Simone WalhoutGGZ-Oost Brabant, Department of Personality Disorders, Helmond, Boxmeer, Oss, the Netherlands.
Bregje de MoorGGZ-Oost Brabant, Department of Personality Disorders, Helmond, Boxmeer, Oss, the Netherlands.
Kasper NikkelsPsyQ Amsterdam, Amsterdam, the Netherlands.
Susanne DalmeijerPsyQ Zaandam, Zaandam, the Netherlands.
Myrte MaarschalkerweerdPsyQ Rotterdam, Rotterdam, the Netherlands.
Joël R van AalderenPsyQ Utrecht, Utrecht, the Netherlands.
Hinde de LangeEmergis, Goes, Netherlands.
Renske WichersIPGGZ Veendam, Veendam, the Netherlands.
Agatha Ph HollanderIPGGZ Groningen, Groningen, the Netherlands.
Silvia M A A EversDepartment of Health Services Research, Care and Public Health Research Institute (CAPHRI) Maastricht University, Maastricht, the Netherlands.
Raoul P P P GrasmanDepartment of Psychological Methods, University of Amsterdam, Amsterdam, the Netherlands.
Arnoud ArntzDepartment of Clinical Psychology, University of Amsterdam, PO Box 15933, Amsterdam, 1001 NK, the Netherlands.
PsyQ · NLUniversity of Amsterdam · NLGGZ Oost Brabant · NLAmsterdam University of Applied Sciences · NLDialyse Centrum Groningen · NLMaastricht University · NLMédecins Sans Frontières · NLTilburg University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the high prevalence of Cluster-C Personality Disorders (PDs) in clinical populations, disease burden, high societal costs and poor prognosis of comorbid disorders, a major gain in health care can be achieved if Cluster-C PDs are adequately treated. The only controlled cost-effectiveness study published so far found Individual Schema Therapy (IST) to be superior to Treatment as Usual (TAU). Group ST (GST) might improve cost-effectiveness as larger numbers can be treated in (>50%) less time compared to IST. However, to date there is no RCT supporting its (cost-) effectiveness. The overall aim of this study is to assess the evidence for GST for Cluster-C PDs and to improve treatment allocation for individual patients. Three main questions are addressed: 1) Is GST for Cluster-C PDs (cost-)effective compared to TAU? 2) Is GST for Cluster-C PDs (cost-) effective compared to IST? 3) Which patient-characteristics predict better response to GST, IST, or TAU?

methodsIn a multicenter RCT, the treatment conditions GST, IST, and TAU are compared in 378 Cluster-C PD patients within 10 sites. GST and IST follow treatment protocols and are completed within 1 year. TAU is the optimal alternative treatment available at the site according to regular procedures. Severity of the Cluster-C PD is the primary outcome, assessed with clinical interviews by independent raters blind for treatment. Functioning and wellbeing are important secondary outcomes. Assessments take place at week 0 (baseline), 17 (mid-GST), 34 (post-GST), 51 (post-booster sessions of GST), and 2 years (FU). Patient characteristics predicting better response to a specific treatment are studied, e.g., childhood trauma, autistic features, and introversion. A tool supporting patients and clinicians in matching treatment to patient will be developed. An economic evaluation investigates the cost-effectiveness and cost-utility from a societal perspective. A process evaluation by qualitative methods explores experiences of participants, loved ones and therapists regarding recovery, quality of life, and improving treatment. DISCUSSION: This study will determine the (cost-)effectiveness of treatments for Cluster-C PDs regarding treatment type as well as optimal matching of patient to treatment and deliver insight into which aspects help Cluster-C-PD patients recover and create a fulfilling life.

trial registrationDutch Trial Register: NL9209 . Registered on 28-01-2021.

Indexed as

Psychotherapy, GroupSchema TherapyCost-Benefit AnalysisHumansMulticenter Studies as TopicPersonality DisordersQuality of LifeTreatment OutcomeCluster-C personality disorderEconomic evaluationGroup schema therapyIndividual schema therapyPersonalized careRandomized controlled trial

Identifiers

PMID36209067
PMCPMC9548126
OpenAlexW4303684363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.